PEN logo

Penumbra (PEN) Company Overview

Profile

Full Name:

Penumbra, Inc.

Sector:

Healthcare

Country:

United States

IPO:

September 18, 2015

Indexes:

Not included

Description:

Penumbra, Inc. is a medical company focused on innovative treatment methods, which designs, develops, manufactures, and sells medical devices. The company's products are aimed at two main segments: vascular diseases and neurosurgery. In both of these markets, the company offers key products: thrombectomy systems - for removing blood clots (thrombi) and embolization systems - for treating patients with various sizes of aneurysms and other vascular and nervous disorders. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.

Key Details

Price

$281.62

Annual Revenue

$1.19 B(+12.86% YoY)

Annual EPS

$0.36(-84.48% YoY)

PE Ratio

828.29

Beta

0.58

Events Calendar

Earnings

Next earnings date:

May 7, 2025

Recent quarterly earnings:

Feb 18, 2025

Recent annual earnings:

Feb 18, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Nov 16, 2014

Analyst ratings

Recent major analysts updates

Feb 19, 25 Wells Fargo
Overweight
Feb 19, 25 UBS
Buy
Feb 19, 25 Truist Securities
Buy
Feb 19, 25 RBC Capital
Outperform
Feb 19, 25 Piper Sandler
Overweight
Feb 19, 25 Needham
Hold
Feb 19, 25 Morgan Stanley
Equal-Weight
Feb 19, 25 JP Morgan
Overweight
Feb 19, 25 Canaccord Genuity
Buy
Feb 19, 25 Baird
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Penumbra?
  • Does Penumbra pay dividends?
  • What sector is Penumbra in?
  • What industry is Penumbra in?
  • What country is Penumbra based in?
  • When did Penumbra go public?
  • Is Penumbra in the S&P 500?
  • Is Penumbra in the NASDAQ 100?
  • Is Penumbra in the Dow Jones?
  • When was Penumbra's last earnings report?
  • When does Penumbra report earnings?
  • Should I buy Penumbra stock now?

What is the ticker symbol for Penumbra?

The ticker symbol for Penumbra is NYSE:PEN

Does Penumbra pay dividends?

No, Penumbra does not pay dividends

What sector is Penumbra in?

Penumbra is in the Healthcare sector

What industry is Penumbra in?

Penumbra is in the Medical Devices industry

What country is Penumbra based in?

Penumbra is headquartered in United States

When did Penumbra go public?

Penumbra's initial public offering (IPO) was on September 18, 2015

Is Penumbra in the S&P 500?

No, Penumbra is not included in the S&P 500 index

Is Penumbra in the NASDAQ 100?

No, Penumbra is not included in the NASDAQ 100 index

Is Penumbra in the Dow Jones?

No, Penumbra is not included in the Dow Jones index

When was Penumbra's last earnings report?

Penumbra's most recent earnings report was on Feb 18, 2025

When does Penumbra report earnings?

The next expected earnings date for Penumbra is May 7, 2025

Should I buy Penumbra stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions